Scholar Rock Holding Corp (SRRK) Stock Price & Analysis
Scholar Rock Holding Corp (SRRK) fell 3.66% to USD 47.67 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
SRRK last closed at USD 49.48; the session ranged USD 47.54–49.95 on volume of 838,705 shares. Market capitalization is $5.71B, with a 52-week range of USD 27.07–58.49 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 47.67 |
|---|---|
| Change | ▼ 3.66% (down) |
| Previous Close | USD 49.48 |
| Open | USD 49.71 |
| Day Range | USD 47.54 – 49.95 |
| 52-Week Range | USD 27.07 – 58.49 |
| Volume | 838,705 shares |
| Market Cap | $5.71B |
| Exchange | NMS |
Technical Analysis (SRRK)
Nexqual's technical model rates SRRK "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.42 (neutral) |
| vs SMA50 | Below (USD 50.03) |
| MACD | -0.28 (negative) |
Analyst Ratings (SRRK)
Wall Street analysts rate SRRK "Strong Buy" based on 16 analysts, with a mean price target of USD 59.31 (range USD 48–70), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 59.31 |
| High Target | USD 70 |
| Low Target | USD 48 |
| Buy / Hold / Sell | 18 / 0 / 0 |
Earnings (SRRK)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.84 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.83 vs est -0.78 ▼ miss |
| 2025-12-31 | USD -0.88 vs est -0.88 ▲ beat |
| 2025-09-30 | USD -0.9 vs est -0.84 ▼ miss |
| 2025-06-30 | USD -0.98 vs est -0.67 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (SRRK)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -138.94% |
| Debt / Equity | 74.52 |
| Current Ratio | 8.64 |
| Total Cash | $479.94M |
| Total Debt | $205.67M |
| Free Cash Flow | $-171.93M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (SRRK)
Nexqual rates Scholar Rock Holding Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $480M cash vs $206M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$303M |
| Efficiency | Critical — ROE -139%, ROA -54.3% |
Ownership (SRRK)
| Insider Ownership | +0.78% |
|---|---|
| Institutional Ownership | +117.18% |
| Shares Outstanding | 119.83M |
| Float | 91.82M |
| Short % of Float | +19.22% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (SRRK)
Scholar Rock Holding Corp is led by David L. Hallal (age 59), CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO & Chairman of the Board | David L. Hallal (age 59) |
|---|---|
| CFO & Treasurer | Vikas Sinha C.A. (age 62) |
| Chief Operating Officer | Robert Keith Woods (age 57) |
| President of R & D, Member of Scientific Advisory Board and Director | Akshay Krishnadas Vaishnaw (age 62) |
| Chief Scientific Officer | Mo Qatanani (age 52) |
Major Backers & Investors (SRRK)
Notable institutional backers of Scholar Rock Holding Corp include FMR, LLC, Siren, L.L.C., Redmile Group, LLC, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.39% |
| Siren, L.L.C. | 9.03% |
| Redmile Group, LLC | 7.57% |
| Fidelity | 6.21% |
| Samsara BioCapital, LLC | 5.76% |
| Wellington Management | 5.61% |
| Price (T.Rowe) Associates Inc | 5.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.47% |
| BlackRock | 7.97% |
| State Street | 5.24% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Scholar Rock Holding Corp's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
- The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
- This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
- The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| REPL | Replimune Group, Inc. | USD 9.7 | ▼ 9.77% |
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
| IDYA | IDEAYA Biosciences, Inc. | USD 35.4 | ▲ 1.14% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.